CIK 0001563880 · Non-accelerated filer<br>Smaller reporting company
Trevi Therapeutics, Inc.
Sign in to watch- Ticker
- TRVI
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 450834299
- Phone
- 203-304-2499
- Business address
- 195 CHURCH STREET, 16TH FLOOR, NEW HAVEN, CT, 06510
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $595,806
- in 1 filing, $596K under 10b5-1 plans
Net −$595,806. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-09-11 | Delfini Lisa Chief Financial Officer | Option exercise 10b5-1 | +2,291 | $0.51 | $1K | 35,105 |
| 2023-09-11 | Delfini Lisa Chief Financial Officer | Sale 10b5-1 | −711 | $2.20 | $2K | 34,394 |
| 2023-09-11 | Delfini Lisa Chief Financial Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −2,291 | 66,460 | ||
| 2023-08-11 | Delfini Lisa Chief Financial Officer | Option exercise 10b5-1 | +2,292 | $0.51 | $1K | 33,496 |
| 2023-08-11 | Delfini Lisa Chief Financial Officer | Sale 10b5-1 | −682 | $2.36 | $2K | 32,814 |
| 2023-08-11 | Delfini Lisa Chief Financial Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −2,292 | 68,751 | ||
| 2023-07-11 | Delfini Lisa Chief Financial Officer | Option exercise 10b5-1 | +2,292 | $0.51 | $1K | 31,891 |
| 2023-07-11 | Delfini Lisa Chief Financial Officer | Sale 10b5-1 | −687 | $2.34 | $2K | 31,204 |
| 2023-07-11 | Delfini Lisa Chief Financial Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −2,292 | 71,043 | ||
| 2023-06-28 | Mathers Edward T Director | Grant or award · Nonstatutory Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2023-06-28 | Colangelo Dominick Director | Grant or award · Nonstatutory Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2023-06-28 | VANLENT ANNE Director | Grant or award · Nonstatutory Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2023-06-28 | Cassella James V Director | Grant or award · Nonstatutory Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2023-06-28 | Heffernan Michael Thomas Director | Grant or award · Nonstatutory Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2023-06-28 | Meeker David P Director | Grant or award · Nonstatutory Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2023-06-20 | Simon Farrell Chief Commercial Officer | Option exercise | +6,250 | $0.51 | $3K | 45,650 |
| 2023-06-20 | Simon Farrell Chief Commercial Officer | Option exercise · Stock Option (right to buy) | −6,250 | 50,000 | ||
| 2023-06-12 | Delfini Lisa Chief Financial Officer | Option exercise 10b5-1 | +2,291 | $0.51 | $1K | 30,209 |
| 2023-06-12 | Delfini Lisa Chief Financial Officer | Sale 10b5-1 | −610 | $2.64 | $2K | 29,599 |
| 2023-06-12 | Delfini Lisa Chief Financial Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −2,291 | 73,335 |
Page 7 of 9 · 179 trades